RecruitingPhase 1ACTRN12617000652370

The impact of Sulpiride (600mg; a dopamine antagonist) on behavioural and electrophysiological measures of visuospatial attention and inhibition

A DAT1 genotype and DRD2 Taq1A genotype, placebo controlled, randomised, double blind, crossover designed study of the effect of Sulpiride (600mg) on visuospatial attention and cognitive control measures (recorded with electroencephalography (EEG) and behavioural tasks) in a sample of 50 healthy adults


Sponsor

Professor Mark Bellgrove

Enrollment

50 participants

Start Date

Nov 11, 2016

Study Type

Interventional

Conditions

Summary

This study will investigate whether temporarily reducing dopamine transmission in the healthy brain affects an individual’s spatial selective attention, that is, the direction in space (left or right) in which an individual’s visual attention naturally falls. By combining this investigation with measures of electrical activity in the brain and genetic testing, we hope to gain a deeper understanding of the mechanisms involved in spatial attention and the influence on these mechanisms of genes implicated in the structure and function of the dopamine system in the brain. Uncovering the mechanisms of spatial attention may help us better understand and treat disorders involving spatial attention deficits, including Attention Deficit Hyperactivity Disorder, which involves an impaired awareness of, and ability to respond to, objects and information in a particular area of visual space.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This study investigates how the brain's attention system is affected when the chemical dopamine is temporarily reduced using a drug called sulpiride. Researchers want to understand whether changes in dopamine affect whether people pay more attention to the left or right side of their visual field. The findings may one day help understand attention disorders like ADHD. You may be eligible if: - You are between 18 and 45 years old - You are right-handed - You are of European (Caucasian) descent - You are neurologically healthy - If female, you must be taking the combined oral contraceptive pill (both progesterone and oestrogen) You may NOT be eligible if: - You currently smoke or have smoked regularly in your lifetime - You have or have had any neurological or psychiatric illness - You have used illicit drugs in the last 6 months - You are pregnant or breastfeeding Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Participants will attend 2 separate sessions, one week apart (on the same day and time). On each occasion, the participant will be given a capsule to swallow containing either 600mg sulpiride or a pl

Participants will attend 2 separate sessions, one week apart (on the same day and time). On each occasion, the participant will be given a capsule to swallow containing either 600mg sulpiride or a placebo sugar pill, according to a randomised, double blind procedure. Participants will commence the study tasks after 180 minutes have elapse (to coincide with peak drug levels) and will complete the tasks within 330 minutes. Observation will occur for a further 30 minutes.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12617000652370